Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | CDH1 | P12830 | 1/20 | 0.44 |
| ▸ | APC | P25054 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.44 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | LDHB | P07195 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12170948 | 0.91 | NPC1 (0.66) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL12170985 | 0.91 | HSD17B1 (0.57) | CTRCNPC1RAB9AL3MBTL1HSD17B1 | |
| SCHEMBL12170941 | 0.88 | KMO (0.56) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL17612316 | 0.87 | HSD17B1 (0.53) | CTRCNPC1RAB9AL3MBTL1HSD17B1 | |
| SCHEMBL4867523 | 0.87 | HSD17B1 (0.53) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL4876329 | 0.87 | HSD17B1 (0.53) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL12170984 | 0.86 | HSD17B1 (0.50) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL12171867 | 0.86 | HSD17B1 (0.49) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL12171953 | 0.85 | HSD17B1 (0.51) | NPC1RAB9AL3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL12171853 | 0.85 | NPC1 (0.53) | CTRCNPC1RAB9AL3MBTL1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101665469-A | Heterocyclic compounds useful as Nurrl activators | NOVARTIS AG | 2010-03-10 | — | — | CN | disclosed |
| CN-100475795-C | Heterocyclic compounds useful as Nurr1 activators | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NOVARTIS AG (CH) | 2006-04-27 | — | — | US | disclosed |
| CN-1747942-A | Heterocyclic compounds useful as Nurr1 activators | NOVARTIS AG (CH) | 2006-03-15 | — | — | CN | disclosed |
| EP-1597243-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072050-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NCOR1, NCOR2, NR4A1 | CTRC 1712/4885NPC1 620/4885RAB9A 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.